Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hakan Gunaydin

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
Journal of Medicinal Chemistry|March 22, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo ActivityRussell F Graceffa, Alessandro A Boezio, Jessica Able, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
Journal of Medicinal Chemistry|March 22, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo ActivityRussell F Graceffa, Alessandro A Boezio, Jessica Able, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Pageof 5